In the US, Sorafenib (sorafenib systemic) is a member of the following drug classes: multikinase inhibitors, VEGF/VEGFR inhibitors and is used to treat Hepatic Tumor, Hepatocellular Carcinoma, Renal Cell Carcinoma and Thyroid Cancer.
US matches:
- Sorafenib
- Sorafenib Tosylate
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
L01XE05
CAS registry number (Chemical Abstracts Service)
0284461-73-0
Chemical Formula
C21-H16-Cl-F3-N4-O3
Molecular Weight
464
Therapeutic Categories
Antineoplastic agent
Angiogenesis inhibitor
Tyrosine kinase inhibitor
Chemical Names
4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N²-methylpyridine-2-carboxamide (WHO)
4-{4-[3-(4-Chlor-3-trifluormethylphenyl)ureido]phenoxy}pyridin-2-carbonsäuremethylamid (IUPAC)
Foreign Names
- Sorafenibum (Latin)
- Sorafenib (German)
- Sorafénib (French)
- Sorafenib (Spanish)
Generic Names
- Sorafenib (OS: USAN)
- BAY 43-9006 (IS: Onyx, Bayer)
- Sorafenib tosylate (OS: USAN)
- Sorafenib tosylat (IS)
Brand Names
- Nexavar
Bayer, Czech Republic; Bayer, Greece; Bayer, Slovenia; Bayer, Argentina; Bayer, Belgium; Bayer, Belize; Bayer, Canada; Bayer, Switzerland; Bayer, Chile; Bayer, Costa Rica; Bayer, Germany; Bayer, Denmark; Bayer, Dominican Republic; Bayer, Spain; Bayer, Finland; Bayer, United Kingdom; Bayer, Guatemala; Bayer, Honduras; Bayer, Croatia (Hrvatska); Bayer, Hungary; Bayer, Ireland; Bayer, Italy; Bayer, Mexico; Bayer, Nicaragua; Bayer, Norway; Bayer, Panama; Bayer, Sweden; Bayer, Slovakia; Bayer, El Salvador; Bayer, United States; Bayer AG, Luxembourg; Bayer Healthcare, Austria; Bayer Santé, France; Bayer Schering, Australia; Bayer Schering, Indonesia; Bayer Schering, Netherlands; Bayer Schering, South Africa
International Drug Name Search
Glossary
IUPAC | International Union of Pure and Applied Chemistry |
IS | Inofficial Synonym |
OS | Official Synonym |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
USAN | United States Adopted Name |
WHO | World Health Organization |
Click for further information on drug naming conventions and International Nonproprietary Names.
No comments:
Post a Comment